Erweiterte Suche

Ms. Mardi C. Dier ist Chief Financial Officer & Executive Vice President bei Ultragenyx Pharmaceutical, Inc. und ein unabhängiges Mitglied des Verwaltungsrats bei Oric Pharmaceuticals, Inc. und Adamas Pharmaceuticals, Inc. Sie ist Mitglied des Board of Directors bei Prelude Therapeutics, Inc. und Oric Pharmaceuticals, Inc. und Adamas Pharmaceuticals, Inc. Frau Dier war zuvor als CFO, Chief Business Officer & Executive VP bei Portola Pharmaceuticals, Inc. beschäftigt, als Vice President-Investor Relations bei Chiron Corp., als Director-Investment Banking bei Prudential Equity Group LLC, als Senior Accountant bei KPMG LLP, als Senior Accountant bei KPMG Peat Marwick LLP und als Director-Investment Banking bei Prudential Securities. Sie war auch im Vorstand von Jewish Vocational Service, Inc. und Futures Strategic Trust. Sie erhielt ihren Bachelor-Abschluss von der Stanford University und einen MBA von der UCLA Anderson School of Management.

Gregory Dier worked as an Associate Research Analyst at Hartford Investment Management Co..
Mr. Dier attended Middlebury College, where he received an undergraduate degree in 2013.

James G.
Dier, who previously worked at Thrivent Investment Management, Inc., held the position of Director.

Louise Dier served as an Independent Non-Executive Director at TClarke Plc from 2019 to 2022.
Prior to that, she worked as a Managing Director at David Chipperfield Architects Ltd., General Manager-United Kingdom at DO & CO Catering-Consult & Beteiligungs GmbH, and Head-Human Resources at IMG Europe Ltd.
She graduated from the University of Cambridge.

Martina Dier has a current job as the Director of Global Communications at TeamViewer SE.

Mardi Loho worked at PT ICTSI Jasa Prima Tbk from 1994 to 2012.
During his time there, he held the position of Independent Commissioner from 2011 to 2012.